Model Development and Prospective Validation to Predict the Response to Neoadjuvant Chemotherapy in Cervical Cancer
N/A
18 Years
70 Years
18 Years
70 Years
Open (Enrolling)
Female
Cervical Cancer
Female
Cervical Cancer
Trial Information
Model Development and Prospective Validation to Predict the Response to Neoadjuvant Chemotherapy in Cervical Cancer
Inclusion Criteria:
- Untreated cervical cancer with FIGO stage Ib-IIIb
- Measurable lesions
- Possible to radical hysterectomy
- Age: 18 and older
- Karnofsky Performance Status≥ 70.
- WBC > 3,000/mm³, Hb > 9.0g/dl, Platelet > 100,000 /mm³, SGOT/SGPT < 60 IU/L, T-Bil
< 1.5 mg/dL, Cr < 1.2 mg/dL, PaO2 > 80 torr, normal ECG
- Written informed consent
Exclusion Criteria:
- Previous history of cancer
- Patients with previous treatment
- Patients without information of clinical risk factors
- Patients who have active infection
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
The clinical and pathological response to neoadjuvant chemotherapy
Safety Issue:
No
Authority:
China: Ministry of Health
Study ID:
GM2011-07-01
NCT ID:
NCT01628757
Start Date:
July 2011
Completion Date:
December 2013
Related Keywords:
- Cervical Cancer
- Uterine Cervical Neoplasms
Name | Location |
|---|
